Revimid: Phase I/II

In an open-label U.S. Phase I/II trial of Revimid in 24 patients with refractory MM, 19 patients (79%) achieved stable

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE